论文部分内容阅读
本文报告145例慢性活动性肝炎(慢活肝)和4例慢性迁延性肝炎(慢迁肝)的近期疗效:强的松单用组效果最差,近期临床治愈率51.2％;强的松和辅酶Q10或植物血凝素并用效果较好,为59.0％;猪胸腺素单用疗效较高,为74.3％;而强的松、胸腺素前后连用,即在停强的松病体免疫力自发上升时续用胸腺素,可提高临床疗效,治愈率达82.4％。胸腺素治疗者,虽HBsAg转阴率仍较低(9.1～21.2％),但获效者半数以上均见HBsAg滴度下降、HBeAg阴转,为HBsAg阴转打下基础。虽不经减量停用强的松续用胸腺素时,约半数病例出现自觉症状和肝功能程度不一的恶化,但均渐次恢复,未见不良后果。
This article reports 145 cases of chronic active hepatitis (slow-living liver) and 4 cases of chronic persistent hepatitis (slow-moving liver) the short-term efficacy: prednisone alone group was the worst, the recent clinical cure rate was 51.2%; prednisone and Coenzyme Q10 or phytohemagglutinin with good results, was 59.0%; pig thymosin single high efficacy, was 74.3%; and prednisone, thymosin before and after the combination, that is, in the stop of loose loose body immunity spontaneously increased Continuous use of thymosin, can improve clinical efficacy, the cure rate was 82.4%. Thymosin treatment, although HBsAg negative rate is still low (9.1 ~ 21.2%), but more than half of those who were seen effective HBsAg titer decreased, HBeAg negative, lay the foundation for HBsAg negative conversion. Although no dose reduction of prednisone with thymosin continued, about half of the cases of subjective symptoms and deterioration of liver function, but were gradually restored, no adverse consequences.